Please login to the form below

Not currently logged in
Email:
Password:

trial failure

This page shows the latest trial failure news and features for those working in and with pharma, biotech and healthcare.

Bayer, Merck’s high-risk heart failure drug comes good in phase 3

Bayer, Merck’s high-risk heart failure drug comes good in phase 3

The first pivotal trial of the oral soluble guanylate cyclase (sGC) stimulator –  VICTORIA – showed that vericiguat was able to reduce the risk of hospitalisation for heart failure or cardiovascular death compared ... the summer when it fluffed a

Latest news

  • Biogen and Eisai revive abandoned aducanumab in shock turnaround Biogen and Eisai revive abandoned aducanumab in shock turnaround

    The initial failure of the drug also fuelled the sentiment that the ‘amyloid hypothesis’ of targeting beta amyloid had finally been exhausted. ... Although Biogen had seen failure in the second trial of aducanumab, it maintains that this is likely

  • Blow for Entresto in latest heart failure trial Blow for Entresto in latest heart failure trial

    Aim of being first in HFpEF in serious doubt. Novartis’ heart failure drug Entrestro (Sacubitril/valsartan) has narrowly missed its primary endpoint in a trial of patients with preserved ejection fraction ... HFpEF). The results came from the

  • Keytruda scores in neoadjuvant triple negative breast cancer combo Keytruda scores in neoadjuvant triple negative breast cancer combo

    In this trial, Keytruda showed improvement regardless of PD-1 status of patients. ... The results are a big boost after the failure of its second line treatment trial, but analysts say that neoadjuvant is currently a small opportunity in triple negative

  • FDA fast-tracks Jardiance for heart failure review FDA fast-tracks Jardiance for heart failure review

    Lilly and Boehringer are pursuing the drug’s use in heart failure patients in their EMPEROR trial programme. ... A product which has opened up the heart failure market in recent years is Novartis’ Entresto.

  • Roche to present new data on Spinraza rival Roche to present new data on Spinraza rival

    One patient died from respiratory failure in a separate European trial of Zolgensma, but the incident was found to be unrelated to the gene therapy following an investigation. ... Last month, another patient death occurred during the phase 3 STR1VE trial,

More from news
Approximately 26 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • For trials without tribulations, we must improve patient experience For trials without tribulations, we must improve patient experience

    The result of this consultation is Havas Lynx Group’s latest white paper‘Patient Centricity on Trial’. ... This kind of simple, practical question can be the difference between success and failure of a clinical trial, and is usually only raised by

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    Avoiding failure. By taking this approach to research, it's possible to avoid one of the major pitfalls facing pharma today – the high cost of late-stage trial failure. ... Particularly when we have high failure rates in late stages in clinical studies,

  • Customer valuation in pharma Customer valuation in pharma

    Multiple studies have pegged the probability of clinical trial success at between 13-20 per cent. ... This estimate has remained constant over decades. Among the major reasons for clinical trial failure are problems that rest squarely in the domain of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Alzheimer's: the numbers we cannot forget

    This is one of the highest clinical trial failure rates in healthcare. ... Failures in these trials have been associated with lack of efficacy, excessive side effects, or challenges in trial execution; leaving patients and HCPs with 5 therapies to choose

  • A forward march for adaptive designs

    For example, poor dose selection in phase II is frequently cited as one of the top causes of late-stage clinical trial failure. ... As such, it has prioritised phase II/III adaptive trial designs as well as other types of study.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...

Infographics